Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri filed an amended beneficial ownership statement with the SEC on November 12, 2026, disclosing a combined 69,965-share position in Aptevo Therapeutics Inc. common stock, representing 3.72% of the class as of September 30, 2026.

Key Highlights

  • Three reporting persons: Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 69,965 shares.
  • Warrant-based holdings: The 69,965 shares represent common stock issuable upon exercise of certain warrants held by the reporting persons, subject to a 9.99% beneficial ownership blocker.
  • Ownership percentage: Each reporting person is listed at 3.72% of Aptevo Therapeutics common stock.
  • Share base used: The percentage is calculated using 1,810,215 shares outstanding as of August 14, 2026, per the issuer's Prospectus dated September 3, 2026.
  • Sole control: Each reporting person holds sole voting power and sole dispositive power over all 69,965 shares, with zero shared voting or dispositive power reported.
  • Amendment filing: This statement is Amendment No. 1 to a prior filing, with the triggering event dated September 30, 2026.

Ayrton Capital's Warrant Position in Aptevo Therapeutics

According to the filing, the 69,965 shares reported by each of the three parties do not represent shares held outright on the open market. Instead, they reflect common stock of Aptevo Therapeutics Inc. (NASDAQ:APVO) issuable upon the exercise of certain warrants. The filing notes that those issuable shares are subject to a 9.99% beneficial ownership blocker, a standard provision that limits the holder's ability to exercise warrants to the extent doing so would cause beneficial ownership to exceed that threshold.

The filing describes the organizational structure of the reporting group: Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, a Cayman Islands exempted company, is the private investment vehicle that holds the warrants. Ayrton Capital LLC, a Delaware limited liability company, serves as the investment manager to that fund. Waqas Khatri is the managing member of Ayrton Capital LLC and also signed as director on behalf of the fund. All three are collectively identified as the "Reporting Persons" in the filing. Aptevo Therapeutics, headquartered at 2401 4th Avenue, Suite 1050, Seattle, WA, is a biopharmaceutical company whose common stock carries a par value of $0.001 per share and is identified by CUSIP number 03835L702.

The filing states that the percentage of class figures for all three reporting persons, each at 3.72%, are based on 1,810,215 shares of common stock outstanding as of August 14, 2026, as stated in the issuer's Prospectus dated September 3, 2026, combined with the 69,965 warrant-issuable shares. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri jointly filed Amendment No. 1 to report beneficial ownership of 69,965 warrant-issuable shares of Aptevo Therapeutics common stock, equal to 3.72% of the class, as of September 30, 2026.